Archimedes announces positive Ph I results for T3 heart candidate
UK drug development firm Archimedes and USA-based T3 therapeutics have released positive Phase I study data of their oral formulation of T3 (lithyronine sodium).
The open-label, single-dose, randomized, crossover, pharmacokinetic, proof-of-concept trial evaluated the bioavailability of oral modified T3 versus immediate-release T3. The candidate exhibited lowered Cmax and prolonged Tmax compared to the existing formulation. The firm claims this shows the drug has great potential in treating hypothyroidism and is expanding its indication to congestive heart failure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze